| 摘要 |
The invention relates to a pharmacological effect of a compound functioning as PPAR³ agonist on a corneal epithelial barrier function. Since the PPAR³ agonist, such as rivoglitazone, DRF-2593, GW-544 and BMS-298585, exhibits an excellent enhancing effect on the corneal epithelial barrier function in an enhancement test of corneal epithelial barrier function, it is useful as a preventive or therapeutic agent for ocular infection, ocular discomfort and the like attributed to a decrease in the corneal epithelial barrier function. In addition, the PPAR³ agonist can enhance the corneal epithelial barrier function in a diabetes patient, a patient with a decrease in the corneal epithelial barrier function due to aging, and a patient who underwent refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser in situ keratomileusis), and cataract surgery.
|
